OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
Trial details
- Registry ID
- NCT04757636
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)NCT04757636 | Opthea Limited | Phase 3 | Terminated | 2025-03-31Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |